映恩生物-B(09606)今日盘中大涨6.41%，引起了市场的广泛关注。
消息面上，中金公司发布研究报告，维持映恩生物-B“跑赢行业”评级，目标价430港元不变，较当前股价有63.4%的上行空间。报告指出，公司2025年收入达18.5亿元，超出该行预期，主要得益于研发合作报销收入超预期。
此外，公司的核心管线全球开发进展顺利。DB-1303已在中国提交针对HER2+乳腺癌的上市申请；DB-1311在2026年2月读出了具有同类最佳潜力的mCRPC数据；DB-1310在非小细胞肺癌和乳腺癌中均显示出初步有效性亮点，并获得了美国FDA的快速通道认定。公司与BioNTech的合作联用试验也预计将在2026年陆续取得数据，后续管线催化事件丰富。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.